The Global Ocular Drug Excipient Market was valued at USD 863 Million in 2023 and is projected to reach USD 1,470.45 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.10% during the forecast period (2024–2032). This growth is being driven by rising prevalence of ocular diseases like glaucoma and macular degeneration, advancements in drug delivery systems such as nanoparticles and sustained-release formulations, and increasing investments in pharmaceutical R&D focused on ophthalmology.

As the pharmaceutical industry advances toward more effective and patient-friendly ophthalmic treatments, the spotlight is on the key excipient suppliers who are driving innovation, stability, and compliance in ocular drug formulations. In this blog, we profile the Top 10 Companies in the Ocular Drug Excipient Industry—a mix of chemical giants, specialty pharma providers, and innovation leaders shaping the future of eye care therapeutics.

---

🔟 1. MilliporeSigma

Headquarters: Burlington, Massachusetts, USA
Key Offering: High-purity excipients, polymers, and stabilizers for ocular formulations

MilliporeSigma, a business of Merck KGaA, stands as a premier provider of pharmaceutical excipients tailored for sensitive ocular applications. Their portfolio supports the development of eye drops, gels, and implants, ensuring biocompatibility and precise drug release. With a strong emphasis on quality control and regulatory compliance, they serve major pharma companies developing treatments for dry eye and retinal disorders.

Innovation Initiatives:

• Advanced polymers for sustained-release ocular drugs
• Partnerships with biopharma for nanoparticle excipients
• Commitment to cGMP manufacturing for global standards

Download FREE Sample Report: Ocular Drug Excipient Market – View in Detailed Research Report

---

9️⃣ 2. IOI Oleochemical

Headquarters: Hamburg, Germany
Key Offering: Lipid-based excipients, emulsifiers for ophthalmic emulsions

IOI Oleochemical is renowned for its natural lipid excipients that enhance the bioavailability of ocular drugs. Operating globally, they supply ingredients critical for emulsion-based eye drops used in treating inflammation and infections. Their products meet stringent purity requirements, making them ideal for preservative-free formulations increasingly demanded in the market.

Innovation Initiatives:

• Development of bio-based lipids for improved ocular penetration
• Collaborations with CMOs for scalable production
• Focus on sustainability in excipient sourcing

---

8️⃣ 3. JRS Pharma

Headquarters: Rosenberg, Germany
Key Offering: Cellulose derivatives, microcrystalline cellulose for viscosity control

JRS Pharma excels in plant-based excipients that provide optimal viscosity and stability in ocular suspensions. Their products are widely used in glaucoma medications and artificial tears, helping maintain pH balance and sterility. With extensive R&D, they address challenges in long-term drug stability for chronic eye conditions.

Innovation Initiatives:

• Specialty celluloses for mucoadhesive ocular delivery
• Investments in cleanroom facilities for pharma-grade production
• Customization services for pharma partners

---

7️⃣ 4. Innophos

Headquarters: Cranbury, New Jersey, USA
Key Offering: Phosphate salts, buffering agents for pH control in eye drops

Innophos specializes in inorganic excipients essential for tonicity adjustment in ophthalmic solutions. They support formulations for anti-allergy and anti-infective eye drugs, ensuring compatibility with sensitive corneal tissues. Their expertise helps pharma companies navigate regulatory hurdles for FDA-approved ocular products.

Innovation Initiatives:

• High-purity phosphates for sterile formulations
• R&D in multifunctional excipients
• Expansion in North American manufacturing capacity

Download FREE Sample Report: Ocular Drug Excipient Market – View in Detailed Research Report

---

6️⃣ 5. InVitria

Headquarters: Fort Collins, Colorado, USA
Key Offering: Animal-free recombinant proteins, stabilizers for biologics in ocular therapies

InVitria provides cell culture media and stabilization excipients for biologics targeting retinal diseases like AMD. Their animal-component-free solutions reduce immunogenicity risks in intravitreal injections, aligning with the shift toward advanced therapies in ophthalmology.

Innovation Initiatives:

• Recombinant albumin alternatives for ocular biologics
• Partnerships with gene therapy developers
• Enhancing stability for long-acting injectables

---

5️⃣ 6. Fuji Chemical Industries

Headquarters: Toyama, Japan
Key Offering: Magnesium carbonate, silica-based excipients for tablets and suspensions

Fuji Chemical Industries delivers excipients that improve flowability and disintegration in ocular solid dosage forms. They play a key role in Asia-Pacific markets, supporting generic and novel drug launches for conditions like conjunctivitis.

Innovation Initiatives:

• Innovative silicates for enhanced ocular drug absorption
• Global supply chain optimization
• R&D collaborations in sustained-release tech

---

4️⃣ 7. Excipact

Headquarters: Brussels, Belgium
Key Offering: Certification and quality-assured excipients for EU compliance

As a certification body, Excipact ensures excipients meet CEP standards for ocular drugs. They facilitate supply chains for pharma firms in Europe, focusing on traceability and purity vital for sterile eye products.

Innovation Initiatives:

• Promoting GMP-certified excipient networks
• Auditing for ocular-specific requirements
• Supporting regulatory harmonization

---

3️⃣ 8. Beneo

Headquarters: Mannheim, Germany
Key Offering: Functional carbohydrates, sweeteners for tonicity in eye drops

Beneo offers sugar-derived excipients that provide osmolality control without irritation. Widely used in over-the-counter ocular lubricants, their products enhance patient comfort and formulation efficacy.

Innovation Initiatives:

• Bioactive carbohydrate excipients
• Sustainable sourcing practices
• Expansion into emerging markets

---

2️⃣ 9. Mallinckrodt Pharmaceuticals

Headquarters: Hazelwood, Missouri, USA
Key Offering: Specialty chemicals, buffers for ophthalmic solutions

Mallinckrodt supplies critical excipients for API compatibility in complex ocular formulations. Their role in U.S. manufacturing supports treatments for uveitis and post-surgical care.

Innovation Initiatives:

• Custom buffering systems
• Supply reliability enhancements
• Focus on API-excipient interaction studies

---

1️⃣ 10. Evonik

Headquarters: Essen, Germany
Key Offering: EUDRAGIT polymers, RESOMER for controlled-release ocular implants

Evonik leads with polymer excipients enabling sustained drug delivery in glaucoma and retinal implants. Their RESOMER biodegradable polymers revolutionized intravitreal therapies, serving top biopharma worldwide.

Innovation Initiatives:

• Next-gen polymers for minimally invasive delivery
• Strategic alliances with ocular biotech firms
• Net-zero ambitions in production

Read Full Report: Ocular Drug Excipient Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Ocular Drug Excipients Is Smarter and More Targeted

The ocular drug excipient market is undergoing a dynamic shift. While traditional stabilizers dominate, the industry is investing heavily in advanced polymers and biologics-compatible materials, novel delivery tech, and compliant supply chains to meet rising demands from personalized eye therapies.

📈 Key Trends Shaping the Market:

• Rapid expansion of nanoparticle and liposomal excipients in EU, US, and Asia-Pacific
• Regulatory mandates for higher purity and traceability by 2030
• Digital tools for excipient-API compatibility testing
• Pharma-excipient alliances for biologics in ophthalmology

Read Full Report: Ocular Drug Excipient Market – View in Detailed Research Report

The companies listed above are not only enabling stable ophthalmic drugs—they’re spearheading the innovation transition in eye health treatments.